Patents by Inventor Teresa Tusié

Teresa Tusié has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods, tools and systems for the prediction and assessment of gestational diabetes
    Patent number: 11085082
    Abstract: Provided is a method of assessing Gestational Diabetes Mellitus (GDM) susceptibility in a female human subject, the method comprising determining the identity of at least one allele at each of at least two positions of single nucleotide polymorphism (SNP) selected from: TCF7L2—rs7903146; IGF2BP2—rs4402960; CDKN2A/B—rs10811661; SLC16A11—rs13342232; FTO—rs8050136; SLC30A8—rs13266634; CDC123/CAMK1D—rs12779790; KCNQ1—rs2237892; CUBN—rs11254363; CUBN—rs1801222; FIGN—rs2119289; FIGN—rs982393; MTHFR—rs1801131; MTHFR—rs1801133; MTR—rs1805087; and SLC19A1—rs1051266, and/or an SNP in linkage disequilibrium therewith at r2>0.8. Also provided are genotyping tools and risk assessment systems for use in the method of assessing GDM susceptibility.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: August 10, 2021
    Assignee: Patia Biopharma S.A. de C.V.
    Inventors: Laureano Simón Buela, Mirella G. Zulueta, Teresa Tusié
  • METHODS, TOOLS AND SYSTEMS FOR THE PREDICTION AND ASSESSMENT OF GESTATIONAL DIABETES
    Publication number: 20200283850
    Abstract: Provided is a method of assessing Gestational Diabetes Mellitus (GDM) susceptibility in a female human subject, the method comprising determining the identity of at least one allele at each of at least two positions of single nucleotide polymorphism (SNP) selected from: TCF7L2—rs7903146; IGF2BP2—rs4402960; CDKN2A/B—rs10811661; SLC16A11—rs13342232; FTO—rs8050136; SLC30A8—rs13266634; CDC123/CAMK1D—rs12779790; KCNQ1—rs2237892; CUBN—rs11254363; CUBN—rs1801222; FIGN—rs2119289; FIGN—rs982393; MTHFR—rs1801131; MTHFR—rs1801133; MTR—rs1805087; and SLC19A1—rs1051266, and/or an SNP in linkage disequilibrium therewith at r2>0.8. Also provided are genotyping tools and risk assessment systems for use in the method of assessing GDM susceptibility.
    Type: Application
    Filed: December 16, 2016
    Publication date: September 10, 2020
    Applicant: Patia Biopharma, S.A. de C.V.
    Inventors: Laureano Simón Buela, Mirella G. Zulueta, Teresa Tusié